Ultragenyx Pharmaceutical Inc. 8-K

What Happened

• On April 2, 2026, Ultragenyx Pharmaceutical Inc. filed an 8‑K reporting that the FDA has accepted for review the company’s resubmitted Biologics License Application (BLA) seeking accelerated approval for UX111 (rebisufligene etisparvovec), an AAV9 gene therapy for Sanfilippo syndrome Type A (MPS IIIA). The FDA set a Prescription Drug User Fee Act (PDUFA) action date of September 19, 2026.

Key Details

• Product: UX111 (rebisufligene etisparvovec), AAV9 gene therapy for MPS IIIA (Sanfilippo Type A).
• Regulatory milestone: FDA accepted the resubmitted BLA for review and assigned a PDUFA action date of September 19, 2026.
• Approval pathway: Company is seeking accelerated approval (as stated in the filing).
• Filing date and signature: Current Report on Form 8‑K filed April 2, 2026; signed by Howard Horn, Executive VP & CFO.

Why It Matters

• For investors, FDA acceptance of the resubmitted BLA and a set PDUFA date are major regulatory milestones that move UX111 closer to potential market approval and commercialization if approved.
• The filing also contains a standard forward‑looking statement caution: the FDA may still require more data or decline accelerated/full approval, and risks (including manufacturing, safety, and regulatory inspection outcomes) could affect timing or chances of approval. Investors should monitor the review process and the September 19, 2026 PDUFA deadline for material updates.